Abbisko and AstraZeneca Form Strategic Collaboration for Lung Cancer Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Strategic Collaboration: Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca to jointly advance the clinical development of an innovative IO-TKI combination therapy for non-small cell lung cancer, marking a significant partnership in oncology treatment.
- Clinical Trial Progress: The Phase I/II clinical study for this combination therapy has received IND approval from the National Medical Products Administration, aiming to evaluate the safety and efficacy of Abbisko's first-in-class oral PD-L1 inhibitor, lumipodlin, in conjunction with AstraZeneca's EGFR-TKI, TAGRISSO.
- Addressing Market Needs: The collaboration targets a long-standing unmet medical need for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer, as existing EGFR-TKI therapies have shown limited efficacy in this patient population, thereby enhancing treatment options.
- Innovative Drug Development: Lumipodlin, as the first oral PD-L1 inhibitor, demonstrates unique selectivity and anti-tumor efficacy, indicating a significant breakthrough in tumor immunotherapy that could potentially reshape the current treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise
14 Analyst Rating
13 Buy
0 Hold
1 Sell
Strong Buy
Current: 189.620
Low
157.61
Averages
213.64
High
252.18
Current: 189.620
Low
157.61
Averages
213.64
High
252.18
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbisko and AstraZeneca Enter Strategic Collaboration for NSCLC Therapy
- Strategic Collaboration: Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca to jointly advance the clinical development of an innovative IO-TKI combination therapy for non-small cell lung cancer, marking a significant partnership in oncology treatment.
- Clinical Trial Initiation: The Phase I/II clinical study for this combination therapy has received IND approval from the National Medical Products Administration, aiming to evaluate the safety and efficacy of Abbisko's first-in-class oral PD-L1 inhibitor lumipodlin in conjunction with AstraZeneca's third-generation EGFR-TKI TAGRISSO.
- Addressing Market Needs: This collaboration targets the long-standing unmet medical need for patients with EGFR-mutated and PD-L1 positive NSCLC, as existing EGFR-TKI therapies have shown limited efficacy in this patient population, thereby enhancing treatment options.
- Innovative Drug Development: Lumipodlin, as a potentially first-in-class oral PD-L1 inhibitor, has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibodies, and if successful, it will provide a new treatment option for patients, strengthening Abbisko's competitive position in oncology drug development.
See More
Abbisko and AstraZeneca Form Strategic Collaboration for Lung Cancer Therapy
- Strategic Collaboration: Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca to jointly advance the clinical development of an innovative IO-TKI combination therapy for non-small cell lung cancer, marking a significant partnership in oncology treatment.
- Clinical Trial Progress: The Phase I/II clinical study for this combination therapy has received IND approval from the National Medical Products Administration, aiming to evaluate the safety and efficacy of Abbisko's first-in-class oral PD-L1 inhibitor, lumipodlin, in conjunction with AstraZeneca's EGFR-TKI, TAGRISSO.
- Addressing Market Needs: The collaboration targets a long-standing unmet medical need for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer, as existing EGFR-TKI therapies have shown limited efficacy in this patient population, thereby enhancing treatment options.
- Innovative Drug Development: Lumipodlin, as the first oral PD-L1 inhibitor, demonstrates unique selectivity and anti-tumor efficacy, indicating a significant breakthrough in tumor immunotherapy that could potentially reshape the current treatment landscape.
See More
FDA to Announce Multiple Therapy Decisions in July
- New Ingredient Approval: On June 9, 2026, the FDA approved Bemotrizinol as a new active ingredient for OTC sunscreens for the first time in over two decades, marking a significant milestone that is expected to drive demand for innovative sunscreen products in the market.
- Children's Monitoring System: The FDA cleared Dexcom's Stelo Glucose Biosensor System on June 12, 2026, making it the first OTC continuous glucose monitor for children, which is anticipated to improve accessibility and effectiveness in managing diabetes among pediatric patients.
- Influenza Treatment Innovation: The FDA approved the first generic version of Xofluza on June 17, 2026, providing a single-dose treatment option for acute influenza in patients aged five and older, which is expected to lower treatment costs and enhance patient options.
- Immunotherapy Breakthrough: The FDA authorized Orca Biosystem's Tregzi, the first Treg cell-based immunotherapy for reducing chronic graft-versus-host disease, offering new treatment hope for blood cancer patients undergoing stem cell transplants.
See More
AstraZeneca's Datroway Recommended for EU Approval in TNBC Treatment
- Regulatory Progress: AstraZeneca's Datroway has received a positive recommendation for approval in the EU for the treatment of metastatic triple-negative breast cancer (TNBC), marking a significant step in its global market expansion.
- Clinical Trial Results: Data from the global, multi-center Phase 3 TROPION-Breast02 trial demonstrated that Datroway improved median overall survival by 5 months in untreated locally recurrent or metastatic TNBC patients, showcasing its significant efficacy over traditional chemotherapy.
- Survival Comparison: The median overall survival for patients treated with Datroway was 23.7 months, compared to 18.7 months for chemotherapy patients, indicating a clear advantage in extending patient survival and potentially changing treatment standards.
- Market Outlook: With FDA approval for HR+/HER- breast cancer expected in 2025, AstraZeneca's market potential in breast cancer treatment is set to expand further, likely contributing positively to the company's future revenue growth.
See More
Enhertu Approved for Six Indications in the EU
- Clinical Trial Results: Daiichi Sankyo and AstraZeneca's Enhertu demonstrated clinically meaningful responses in three phase 2 trials, with a confirmed objective response rate of 52.3% in DESTINY-PanTumor02, providing a new treatment option for HER2 positive tumor patients and marking a significant advancement in precision medicine.
- EU Approval: Enhertu has been approved in the EU as a monotherapy for adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior treatment and have no satisfactory alternatives, showcasing the company's commitment to innovation in cancer treatment.
- Safety Profile: The safety profile of Enhertu was consistent with previous trials, with no new safety concerns identified, and grade 3 or 4 adverse reactions occurring at a rate of 18.5%, which instills confidence in its application across various tumor types.
- Financial Milestone: Following this EU approval, AstraZeneca is required to pay Daiichi Sankyo a milestone payment of $25 million, further solidifying the collaboration between the two companies in the HER2 positive tumor treatment space.
See More
CelLBxHealth PLC Earnings Review and Outlook
- Enhanced Partnerships: CelLBxHealth PLC has established a master service agreement with AstraZeneca and initiated clinical studies with Advent Health, which not only enhances its market presence but also lays the groundwork for future commercial opportunities.
- Significant Cost Savings: The company has streamlined operations, resulting in annualized cash operating cost reductions of over $6.6 million, a move that will help improve financial conditions and enhance profitability.
- Broad Market Opportunity: With a projected market opportunity exceeding $1 billion by 2031 for precision cancer diagnostics, CelLBxHealth PLC has solidified its credibility in oncology through a strong patent portfolio and over 120 peer-reviewed publications.
- Clear Financial Challenges: Despite the potential in the market, the company's revenue decreased from $2.9 million in 2024 to $1.4 million in 2025, indicating challenging market conditions and slow commercial conversion, with an operating loss of $19.2 million, highlighting the urgent need for additional funding to ensure financial sustainability.
See More
Abbisko and AstraZeneca Enter Strategic Collaboration for NSCLC Therapy
- Strategic Collaboration: Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca to jointly advance the clinical development of an innovative IO-TKI combination therapy for non-small cell lung cancer, marking a significant partnership in oncology treatment.
- Clinical Trial Initiation: The Phase I/II clinical study for this combination therapy has received IND approval from the National Medical Products Administration, aiming to evaluate the safety and efficacy of Abbisko's first-in-class oral PD-L1 inhibitor lumipodlin in conjunction with AstraZeneca's third-generation EGFR-TKI TAGRISSO.
- Addressing Market Needs: This collaboration targets the long-standing unmet medical need for patients with EGFR-mutated and PD-L1 positive NSCLC, as existing EGFR-TKI therapies have shown limited efficacy in this patient population, thereby enhancing treatment options.
- Innovative Drug Development: Lumipodlin, as a potentially first-in-class oral PD-L1 inhibitor, has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibodies, and if successful, it will provide a new treatment option for patients, strengthening Abbisko's competitive position in oncology drug development.
See More
Abbisko and AstraZeneca Form Strategic Collaboration for Lung Cancer Therapy
- Strategic Collaboration: Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca to jointly advance the clinical development of an innovative IO-TKI combination therapy for non-small cell lung cancer, marking a significant partnership in oncology treatment.
- Clinical Trial Progress: The Phase I/II clinical study for this combination therapy has received IND approval from the National Medical Products Administration, aiming to evaluate the safety and efficacy of Abbisko's first-in-class oral PD-L1 inhibitor, lumipodlin, in conjunction with AstraZeneca's EGFR-TKI, TAGRISSO.
- Addressing Market Needs: The collaboration targets a long-standing unmet medical need for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer, as existing EGFR-TKI therapies have shown limited efficacy in this patient population, thereby enhancing treatment options.
- Innovative Drug Development: Lumipodlin, as the first oral PD-L1 inhibitor, demonstrates unique selectivity and anti-tumor efficacy, indicating a significant breakthrough in tumor immunotherapy that could potentially reshape the current treatment landscape.
See More
FDA to Announce Multiple Therapy Decisions in July
- New Ingredient Approval: On June 9, 2026, the FDA approved Bemotrizinol as a new active ingredient for OTC sunscreens for the first time in over two decades, marking a significant milestone that is expected to drive demand for innovative sunscreen products in the market.
- Children's Monitoring System: The FDA cleared Dexcom's Stelo Glucose Biosensor System on June 12, 2026, making it the first OTC continuous glucose monitor for children, which is anticipated to improve accessibility and effectiveness in managing diabetes among pediatric patients.
- Influenza Treatment Innovation: The FDA approved the first generic version of Xofluza on June 17, 2026, providing a single-dose treatment option for acute influenza in patients aged five and older, which is expected to lower treatment costs and enhance patient options.
- Immunotherapy Breakthrough: The FDA authorized Orca Biosystem's Tregzi, the first Treg cell-based immunotherapy for reducing chronic graft-versus-host disease, offering new treatment hope for blood cancer patients undergoing stem cell transplants.
See More
AstraZeneca's Datroway Recommended for EU Approval in TNBC Treatment
- Regulatory Progress: AstraZeneca's Datroway has received a positive recommendation for approval in the EU for the treatment of metastatic triple-negative breast cancer (TNBC), marking a significant step in its global market expansion.
- Clinical Trial Results: Data from the global, multi-center Phase 3 TROPION-Breast02 trial demonstrated that Datroway improved median overall survival by 5 months in untreated locally recurrent or metastatic TNBC patients, showcasing its significant efficacy over traditional chemotherapy.
- Survival Comparison: The median overall survival for patients treated with Datroway was 23.7 months, compared to 18.7 months for chemotherapy patients, indicating a clear advantage in extending patient survival and potentially changing treatment standards.
- Market Outlook: With FDA approval for HR+/HER- breast cancer expected in 2025, AstraZeneca's market potential in breast cancer treatment is set to expand further, likely contributing positively to the company's future revenue growth.
See More
Enhertu Approved for Six Indications in the EU
- Clinical Trial Results: Daiichi Sankyo and AstraZeneca's Enhertu demonstrated clinically meaningful responses in three phase 2 trials, with a confirmed objective response rate of 52.3% in DESTINY-PanTumor02, providing a new treatment option for HER2 positive tumor patients and marking a significant advancement in precision medicine.
- EU Approval: Enhertu has been approved in the EU as a monotherapy for adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior treatment and have no satisfactory alternatives, showcasing the company's commitment to innovation in cancer treatment.
- Safety Profile: The safety profile of Enhertu was consistent with previous trials, with no new safety concerns identified, and grade 3 or 4 adverse reactions occurring at a rate of 18.5%, which instills confidence in its application across various tumor types.
- Financial Milestone: Following this EU approval, AstraZeneca is required to pay Daiichi Sankyo a milestone payment of $25 million, further solidifying the collaboration between the two companies in the HER2 positive tumor treatment space.
See More
CelLBxHealth PLC Earnings Review and Outlook
- Enhanced Partnerships: CelLBxHealth PLC has established a master service agreement with AstraZeneca and initiated clinical studies with Advent Health, which not only enhances its market presence but also lays the groundwork for future commercial opportunities.
- Significant Cost Savings: The company has streamlined operations, resulting in annualized cash operating cost reductions of over $6.6 million, a move that will help improve financial conditions and enhance profitability.
- Broad Market Opportunity: With a projected market opportunity exceeding $1 billion by 2031 for precision cancer diagnostics, CelLBxHealth PLC has solidified its credibility in oncology through a strong patent portfolio and over 120 peer-reviewed publications.
- Clear Financial Challenges: Despite the potential in the market, the company's revenue decreased from $2.9 million in 2024 to $1.4 million in 2025, indicating challenging market conditions and slow commercial conversion, with an operating loss of $19.2 million, highlighting the urgent need for additional funding to ensure financial sustainability.
See More
